Page 24 - IMO-2-1

Innovative Medicines & Omics Incretin mimetics in diabetes management

92. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, doi: 10.1016/j.ajo.2024.04.010
GLP-1 and glucagon receptor agonist, for people with type 2 97. Liu C, Zou Y, Qian H. GLP-1R agonists for treating obesity:
diabetes: A randomised, double-blind, placebo and active- A patent review (2015-present). Expert Opin Ther Pat.
controlled, parallel-group, phase 2 trial conducted in the 2020;30(10):781-794.
USA. Lancet. 2023;402(10401):529-544.
doi: 10.1080/13543776.2020.1811851
doi: 10.1016/S0140-6736(23)01053-X
98. Gong B, Yao Z, Zhou C, Wang W, Sun L, Han J. Glucagon-
93. Naeem M, Imran L, Banatwala UESS. Unleashing the power of like peptide-1 analogs: Miracle drugs are blooming? Eur J
retatrutide: A possible triumph over obesity and overweight: Med Chem. 2024;269:116342.
A correspondence. Health Sci Rep. 2024;7(2):e1864.
doi: 10.1016/j.ejmech.2024.116342
doi: 10.1002/hsr2.1864
99. Cowart K. Oral semaglutide: First-in-class oral GLP-1
94. Caturano A, Galiero R, Rocco M, et al. Modern challenges
in type 2 diabetes: Balancing new medications with receptor agonist for the treatment of type 2 diabetes mellitus.
multifactorial care. Biomedicines. 2024;12(9):2039. Ann Pharmacother. 2019; 54(5):478-485.
doi: 10.1177/1060028019889064
doi: 10.3390/biomedicines12092039
100. Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-
95. Eleftheriadou A, Riley D, Zhao SS, et al. Risk of diabetic
retinopathy and diabetic macular oedema with sodium- like peptide-1 receptor agonists associated gastrointestinal
glucose cotransporter 2 inhibitors and glucagon-like adverse events: A cross-sectional analysis of the national
peptide 1 receptor agonists in type 2 diabetes: A real-world institutes of health all of us cohort. Pharmaceuticals (Basel).
data study from a global federated database. Diabetologia. 2024;17(2):199.
2024;67:1271-1281. doi: 10.3390/ph17020199
doi: 10.1007/s00125-024-06132-5 101. Sztanek F, Tóth LI, Pető A, Hernyák M, Diószegi Á,
Harangi M. New developments in pharmacological
96. Wai KM, Mishra K, Koo E, et al. Impact of GLP-1 agonists
and SGLT-2 inhibitors on diabetic retinopathy progression: treatment of obesity and type 2 diabetes-beyond and within
An aggregated electronic health record data study. Am J GLP-1 receptor agonists. Biomedicines. 2024;12(6):1320.
Ophthalmol. 2024;265:39-47. doi: 10.3390/biomedicines12061320

Volume 2 Issue 1 (2025) 18 doi: 10.36922/imo.4911